Saki Hayashida
Overview
Explore the profile of Saki Hayashida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miyoshi T, Otsuru M, Morishita K, Omori K, Miura K, Hayashida S, et al.
Cureus
. 2025 Feb;
17(2):c210.
PMID: 39911288
[This corrects the article DOI: 10.7759/cureus.62855.].
2.
Miyoshi T, Otsuru M, Morishita K, Omori K, Miura K, Hayashida S, et al.
Cureus
. 2024 Jul;
16(6):e62855.
PMID: 39036251
Purpose Medication-related osteonecrosis of the jaw (MRONJ) is a serious side effect of antiresorptive agents such as bisphosphonates (BPs) and denosumab (DMB). We investigated whether a difference exists between BP-...
3.
Suyama K, Otsuru M, Nakamura N, Morishita K, Miyoshi T, Omori K, et al.
J Dent Sci
. 2024 Jul;
19(3):1758-1769.
PMID: 39035329
Background /purpose: The standard treatment for medication-related osteonecrosis of the jaw (MRONJ) is surgery. However, reports on the appropriate extent of bone resection are few. We aimed to examine the...
4.
Otsuru M, Soutome S, Hayashida S, Morishita K, Yanamoto S, Umeda M
Int J Surg Case Rep
. 2023 Feb;
104:107932.
PMID: 36801766
Introduction And Importance: Osteonecrosis of the jaw resulting from treatment with antiresorptive agents, such as bisphosphonates and denosumab, is widely recognized as medication-related osteonecrosis of the jaw (MRONJ). However, to...
5.
Omori K, Otsuru M, Morishita K, Hayashida S, Suyama K, Naruse T, et al.
Int J Environ Res Public Health
. 2022 Sep;
19(17).
PMID: 36078614
In patients with osteoporosis receiving antiresorptive agents (ARs), it has been widely practiced to withdraw ARs for several months before tooth extraction and during treatment if medication-related osteonecrosis of the...
6.
Soutome S, Otsuru M, Hayashida S, Naruse T, Morishita K, Kurihara K, et al.
BMC Oral Health
. 2022 Jul;
22(1):287.
PMID: 35841016
Background: Increased bacterial presence in the tongue coating and thereby, the saliva, may be a risk factor for postoperative complications such as surgical site infection or postoperative pneumonia after cancer...
7.
Kojima Y, Soutome S, Otsuru M, Hayashida S, Sakamoto Y, Sawada S, et al.
Int J Environ Res Public Health
. 2022 Jul;
19(13).
PMID: 35805513
Recent reports have shown that better treatment outcomes are obtained with surgical therapy in patients with medication-related osteonecrosis of the jaw (MRONJ) than with conservative therapy. However, conservative treatment is...
8.
Morishita K, Soutome S, Otsuru M, Hayashida S, Murata M, Sasaki M, et al.
Sci Rep
. 2022 Jul;
12(1):11545.
PMID: 35799050
A drug holiday of 3 months does not promote separation of sequestra and is not correlated with treatment outcomes after surgical therapy in osteoporosis patients who receive antiresorptive agents and...
9.
Otsuru M, Hayashida S, Morishita K, Murata M, Soutome S, Sasaki M, et al.
Int J Environ Res Public Health
. 2022 Jun;
19(12).
PMID: 35742679
Although maxillary sinusitis often occurs in patients with medication-related osteonecrosis of the jaw (MRONJ) of the upper jaw, there have been few reports on the treatment and outcomes for maxillary...
10.
Soutome S, Otsuru M, Murata M, Morishita K, Omori K, Suyama K, et al.
Support Care Cancer
. 2022 May;
30(9):7241-7248.
PMID: 35587291
Purpose: To retrospectively investigate whether apical lesion, alveolar bone loss, probing pocket depth, or local infectious symptoms were associated with the onset of medication-related osteonecrosis of the jaw (MRONJ) in...